Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus suprachoroidal triamcinolone for central retinal vein occlusion
ACTRN12622000267752Phase 2Completed
- Sponsor
- Salahuddin
- Start
- Jul 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and triamcinolone in central retinal vein occlusion (CRVO), sponsored by Salahuddin. Primary endpoint: Macular thickness. Started Jul 2021; status: completed.
02
Drugs
bevacizumabtriamcinolone
03
Conditions
central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on ACTRN12622000267752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000267752.